FindTrial
Sign In

Drug to control bleeding in major spine surgery

Impact of Tranexamic Acid on Red Blood Cell Transfusion in Spinal Surgeryâ??â??â??â??â??â??â??

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2012/01/002357
Enrollment
50
Registered
2012-01-20
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Patients requiring Spine fusion surgery

Interventions

Intervention1: Tranexamic acid: The administration of tranexamic acid/placebo will start following the induction of general anesthesia. Bolus dose of 30 mg/kg of tranexamic acid followed by a continuo

Sponsors

AOSpine India
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: • Patients aged 18 to 65 years • Patients undergoing spinal surgery with expected significant blood loss • Physical status ASA I to III inclusive

Exclusion criteria

Exclusion criteria: • Allergy to tranexamic acid • Epilepsy • Minimally invasive surgery • Unwillingness to receive blood transfusion • Known coagulopathy/hepatic disease • Previous thromboembolic events • Pregnancy • Renal impairment • Colour blindness

Design outcomes

Primary

MeasureTime frame
Primary Measures â?¢% of patient transfusions â?¢Number of transfusions Secondary Measures â?¢Measured blood losses â?¢Morbidity Timepoint: 72 hours—

Secondary

MeasureTime frame
Measured blood losses oMorbidity oMortality oLength of stay in the hospital oCalculated blood losses Timepoint: 30 days—

Countries

India

Contacts

Public ContactDr Rupinder Pal Singh Chahal

Sir ganga Ram Hospital

rupinder72@hotmail.com9212545550

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026